Global distribution of the CCR2-641/CCR5-59653T HIV-1 disease-protective haplotype
AuthorMartinson, J. J.
Moore, J. P.
Kostrikis, Leontios G.
Google Scholar check
MetadataShow full item record
Objectives: Several natural polymorphisms in the genes for the human CC-chemokine receptors CCR5 and CCR2 are associated with HIV-1 disease. The CCR2-641 genetic variant [a G to A substitution resulting in a valine (V) to isoleucine (I) change at position 64] is in strong linkage disequilibrium with a mutation within the CCR5 regulatory region (CCR5-59653T). Individuals with two CCR2-641 alleles are not resistant to sexual transmission of HIV-1, but progress significantly more slowly to HIV-1 disease. It is therefore important to determine the global distributions of CCR2-641 and CCR5-59653T genetic variants and define the degree of linkage between them. Design and methods: We have developed molecular beacon-based, real-time PCR allele discrimination assays for all three chemokine receptor mutations, and used these spectral genotyping assays to genotype 3923 individuals from a globally distributed set of 53 populations. Results: CCR2-641 and CCR5-59653T genetic variants are found in almost all populations studied: their allele frequencies are greatest (~35%) in Africa and Asia but decrease in Northern Europe. We confirm that CCR2-641 is in strong linkage disequilibrium with CCR5-59653T (96.92% of individuals had the same genotype for both CCR2-641 and CCR5-59653T polymorphisms). Conclusions: The greater geographical distribution of the CCR2-641/CCR5-59653T haplotype compared with that of CCR5-Δ32 suggests that it is a much older mutation whose origin predates the dispersal of modern humans. (C) 2000 Lippincott Williams and Wilkins.
Showing items related by title, author, creator and subject.
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial Skarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, Anna; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C.; Pectasides, Dimitrios; Gogas, H.; Aravantinos, Gerasimos; Pavlidis, Nicholas; Arapantoni, P.; Skarlos, Dimosthenis V.; Fountzilas, George (2012)Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate ...
Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome Pentheroudakis, George; Angouridakis, N.; Wirtz, R. M.; Nikolaou, A.; Kalogeras, K. T.; Pavlidis, Nicholas; Fountzilas, George (2009)Locoregional recurrence is the most common failure pattern in patients with head and neck squamous cell carcinoma (HNSCC). We retrospectively identified 41 HNSCC patients with locoregional relapse and used kinetic reverse ...
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary Krikelis, D.; Pentheroudakis, George; Goussia, Anna; Siozopoulou, V.; Bobos, M.; Petrakis, Dimitrios; Stoyianni, A.; Golfinopoulos, Vassilis; Cervantes, A.; Ciuleanu, T.; Fountzilas, George; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2012)Cancer of unknown primary (CUP) is a heterogeneous entity, managed on the basis of "one size fits all" therapeutic concepts; insights into the molecular biology of CUP are urgently needed. We retrospectively examined the ...